JBM  Vol.6 No.12 , December 2018
The Growing Evidence for Photobiomodulation as a Promising Treatment for Alzheimer’s Disease
Show more
Despite the current belief that there is no effective treatment for Alzheimer’s Disease (AD), one emerging modality may change this belief: Photobiomodulation (PBM). It has credible mechanisms and growing evidence to support its case. Transcranial PBM for AD is a single intervention with multiple pathway mechanisms stemming from delivering low energy near infrared (NIR) light to the mitochondria in brain cells. The mechanisms involve the activation of gene transcription that lead to neuronal recovery, removal of toxic plaques, normalizing network oscillations that can lead to improved cognition and functionality. When PBM is delivered at 810 nm wavelength and pulsed at 40 Hz, early evidence suggests that very significant outcomes are possible. Literature related to PBM and AD has covered in vitro cellular, animal and human case reports, with promising results. They warrant robust randomized trials which are either ongoing or ready to start. The evidence in human studies is manifested in assessment scales such ADAS-cog, MMSE, and ADAS-ADL, and are supported by fMRI imaging and EEG.
Cite this paper: Lim, L. (2018) The Growing Evidence for Photobiomodulation as a Promising Treatment for Alzheimer’s Disease. Journal of Biosciences and Medicines, 6, 100-110. doi: 10.4236/jbm.2018.612010.

[1]   Gardner, E. (2017) Alzheimer’s Drugs: Will 2017 Bring Better News?

[2]   Dubois, B., Padovani, A., Scheltens, P., Rossi, A. and Dell'Agnello, G. (2016) Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. J Alzheimers Dis, 49, 617-631.

[3]   Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., et al. (1991) Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease. Nature, 349, 704-706.

[4]   Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M. and St George-Hyslop, P.H. (1995) Cloning of a Gene Bearing Missense Mutations in Early-Onset Familial Alzheimer's Disease. Nature, 375, 754-760.

[5]   Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W. and Pericak-Vance, M.A. (1993) Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families. Science, 261, 921-923.

[6]   Herrup, K. (2015) The Case for Rejecting the Amyloid Cascade Hypothesis. Nat Neurosci, 18, 794-799.

[7]   Iqbal, K., Liu, F. and Gong, C.X. (2014) Alzheimer Disease Therapeutics: Focus on the Disease and Not Just Plaques and Tangles. Biochem Pharmacol, 88, 631-639.

[8]   Karran, E. and Hardy, J. (2014) A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease. Ann Neurol, 76, 185-205.

[9]   Swerdlow, R.H., Burns, J.M. and Khan, S.M. (2014) The Alzheimer's Disease Mito-Chondrial Cascade Hypothesis: Progress and Perspectives. Biochim Biophys Acta, 1842, 1219-1231.

[10]   Brion, J.P. (1998) Neurofibrillary Tangles and Alzheimer's Disease. Eur Neurol, 40, 130-140.

[11]   Mandelkow, E.M. and Mandelkow, E. (2012) Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration. Cold Spring Harb Perspect Med, 2, a006247.

[12]   Friedland-Leuner, K., Stockburger, C., Denzer, I., Eckert, G.P. and Muller, W.E. (2014) Mitochondrial Dysfunction: Cause and Consequence of Alzheimer's Disease. Prog Mol Biol Transl Sci, 127, 183-210.

[13]   Gibson, G.E. and Shi, Q. (2010) A Mitocentric View of Alzheimer's Disease Suggests Multi-Faceted Treatments. J Alzheimers Dis, 20, S591-S607.

[14]   Kapogiannis, D. and Mattson, M.P. (2011) Disrupted Energy Metabolism and Neuronal Circuit Dysfunction in Cognitive Impairment and Alzheimer's Disease. Lancet Neurol, 10, 187-198.

[15]   Leuner, K., Muller, W.E. and Reichert, A.S. (2012) From Mitochondrial Dysfunction to Amyloid Beta Formation: Novel Insights into the Pathogenesis of Alzheimer's Disease. Mol Neurobiol, 46, 186-193.

[16]   Muller, W.E., Eckert, A., Kurz, C., Eckert, G.P. and Leuner, K. (2010) Mitochondrial Dysfunction: Common Final Pathway in Brain Aging and Alzheimer's Disease—Therapeutic Aspects. Mol Neurobiol, 41, 159-171.

[17]   Gabuzda, D., Busciglio, J., Chen, L.B., Matsudaira, P. and Yankner, B.A. (1994) Inhibition of Energy Metabolism Alters the Processing of Amyloid Precursor Protein and Induces a Potentially Amyloidogenic Derivative. J Biol Chem, 269, 13623-13628.

[18]   Gasparini, L., Racchi, M., Benussi, L., Curti, D., Binetti, G., Bianchetti, A. and Govoni, S. (1997) Effect of Energy Shortage and Oxidative Stress on Amyloid Precursor Protein Metabolism in COS Cells. Neurosci Lett, 231, 113-117.

[19]   Webster, M.T., Pearce, B.R., Bowen, D.M. and Francis, P.T. (1998) The Effects of Perturbed Energy Metabolism on the Processing of Amyloid Precursor Protein in PC12 Cells. J Neural Transm (Vienna), 105, 839-853.

[20]   Hamblin, M.R. (2016) Shining Light on the Head: Photobiomodulation for Brain Disorders. BBA Clin, 6, 113-124.

[21]   Wu, S., Zhou, F., Wei, Y., Chen, W.R., Chen, Q. and Xing, D. (2014) Cancer Phototherapy via Selective Photoinactivation of Respiratory Chain Oxidase to Trigger a Fatal Superoxide Anion Burst. Antioxid Redox Signal, 20, 733-746.

[22]   Farivar, S., Malekshahabi, T. and Shiari, R. (2014) Biological Effects of Low Level Laser Therapy. J Lasers Med Sci, 5, 58-62.

[23]   Passarella, S. and Karu, T. (2014) Absorption of Monochromatic and Narrow Band Radiation in the Visible and Near IR by Both Mitochondrial and Non-Mitochondrial Photoacceptors Results in Photobiomodulation. J PhotochemPhotobiol B, 140, 344-358.

[24]   Lane, N. (2006) Cell Biology: Power Games. Nature, 443, 901-903.

[25]   Waypa, G.B., Smith, K.A. and Schumacker, P.T. (2016) O2 Sensing, Mitochondria and ROS Signaling: The Fog Is Lifting. Mol Aspects Med, 47-48, 76-89.

[26]   Bindoli, A. and Rigobello, M.P. (2013) Principles in Redox Signaling: From Chemistry to Functional Significance. Antioxid Redox Signal, 18, 1557-1593.

[27]   Poyton, R.O. and Ball, K.A. (2011) Therapeutic Photobiomodulation: Nitric Oxide and a Novel Function of Mitochondrial Cytochrome C Oxidase. Discov Med, 11, 154-159.

[28]   Hu, X., Das, B., Hou, H., He, W. and Yan, R. (2018) BACE1 Deletion in the Adult Mouse Reverses Preformed Amyloid Deposition and Improves Cognitive Functions. J Exp Med, 215, 927-940.

[29]   De Taboada, L., Yu, J., El-Amouri, S., Gattoni-Celli, S., Richieri, S., McCarthy, T, and Kindy, M.S. (2011) Transcranial Laser Therapy Attenuates Amyloid-Beta Peptide Neuropathology in Amyloid-Beta Protein Precursor Transgenic Mice. J Alzheimers Dis, 23, 521-535.

[30]   Purushothuman, S., Johnstone, D.M., Nandasena, C., Mitrofanis, J. and Stone, J. (2014) Photobiomodulation with Near Infrared Light Mitigates Alzheimer's Disease-Related Pathology in Cerebral Cortex—Evidence from Two Transgenic Mouse Models. Alzheimers Res Ther, 6, 2.

[31]   Saltmarche, A.E., Naeser, M.A., Ho, K.F., Hamblin, M.R. and Lim, L. (2017) Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial plus Intranasal Photobiomodulation: Case Series Report. Photomed Laser Surg, 35, 432-441.

[32]   Berman, M.H., Halper, J.P., Nichols, T.W., Jarrett, H., Lundy, A. and Huang, J.H. (2017) Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition. J Neurol Neurosci, 8.

[33]   Zomorrodi, R., Saltmarche, A.E., Loheswaran, G., Ho, K.F. and Lim, L. (2017) Complementary EEG Evidence for a Significantly Improved Alzheimer’s Disease Case after Photobiomodulation Treatment. Paper Presented at the 26th Annual Scientific Conference, Canadian Academy of Geriatric Psychiatry Toronto.

[34]   Chao, L. (In Press) Effects of Home Photobiomodulation Treatments Oncognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial. Photomed Laser Surg.

[35]   Lim, L. (2017) Vielight Neuro RX Gamma—Feasibility Pilot.

[36]   Andrews-Hanna, J.R., Snyder, A.Z., Vincent, J.L., Lustig, C., Head, D., Raichle, M. E. and Buckner, R.L. (2007) Disruption of Large-Scale Brain Systems in Advanced Aging. Neuron, 56, 924-935.

[37]   Greicius, M.D., Srivastava, G., Reiss, A.L. and Menon, V. (2004) Default-Mode Network Activity Distinguishes Alzheimer's Disease from Healthy Aging: Evidence from Functional MRI. Proc Natl Acad Sci USA, 101, 4637-4642.

[38]   Beason-Held, L.L. (2011) Dementia and the Default Mode. Curr Alzheimer Res, 8, 361-365.

[39]   Binnewijzend, M.A., Schoonheim, M.M., Sanz-Arigita, E., Wink, A.M., van der Flier, W.M., Tolboom, N. and Barkhof, F. (2012) Resting-State fMRI Changes in Alzheimer's Disease and Mild Cognitive.

[40]   Buckner, R.L., Sepulcre, J., Talukdar, T., Krienen, F.M., Liu, H., Hedden, T. and Johnson, K.A. (2009) Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease. J Neurosci, 29, 1860-1873.

[41]   Damoiseaux, J.S., Prater, K.E., Miller, B.L. and Greicius, M.D. (2012) Functional Connectivity Tracks Clinical Deterioration in Alzheimer’s Disease. Neurobiol Aging, 33, 828 e819-830.

[42]   Buckner, R.L., Snyder, A.Z., Shannon, B.J., LaRossa, G., Sachs, R., Fotenos, A.F. and Mintun, M.A. (2005) Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, And Memory. J Neurosci, 25, 7709-7717.

[43]   Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N. and Mucke, L. (2007) Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease. Neuron, 55, 697-711.

[44]   Verret, L., Mann, E.O., Hang, G.B., Barth, A.M., Cobos, I., Ho, K. and Palop, J.J. (2012) Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model. Cell, 149, 708-721.

[45]   Selkoe, D.J. (1996) Amyloid Beta-Protein and the Genetics of Alzheimer's Disease. J Biol Chem, 271, 18295-18298.

[46]   Iaccarino, H.F., Singer, A.C., Martorell, A.J., Rudenko, A., Gao, F., Gillingham, T.Z. and Tsai, L.H. (2016) Gamma frequency Entrainment Attenuates Amyloid Load and Modifies Microglia. Nature, 540, 230-235.